Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
04 avr. 2023 06h45 HE
|
Cingulate Inc.
Trial On Track for 3Q 2023 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
New Study: Brain Training Improve Clinical and Cognitive Measures in Autism
27 mars 2023 08h00 HE
|
Posit Science
SAN FRANCISCO, March 27, 2023 (GLOBE NEWSWIRE) -- New results from a study of brain training among people with autism spectrum disorder (ASD) show significant gains in clinical and cognitive...
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
13 mars 2023 06h45 HE
|
Cingulate Inc.
Go-to-Market Solution Provides Full Commercial Support for the First, True Entire Active-Day Medication Designed to treat ADHD Indegene Model Geared for Efficient National Commercial Launch in...
Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
10 mars 2023 16h05 HE
|
Cingulate Inc.
CTx-1301 Phase 3 Adult Dose-Optimization Study Ongoing; Results Expected 3Q 2023 Positive Top-Line Data from CTx-1301 Fed/Fast Study Announced, Full Results Submitted for Presentation at Forthcoming...
NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD
01 mars 2023 11h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced a new option for patients and caregivers seeking a telehealth evaluation for the Monarch eTNS System®. NeuroSigma is a Los...
Applications for The Southport School’s Summer Programs Are Now Being Accepted
23 févr. 2023 16h33 HE
|
The Southport School Inc
SOUTHPORT, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- The Southport School (TSS), a private day school for neurodiverse children who have language-based learning differences and/or ADHD, today...
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
23 févr. 2023 16h30 HE
|
Cingulate Inc.
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., Feb. 23, 2023 (GLOBE NEWSWIRE) --...
Therapeutic Targeting of the Microbiome for Neurodevelopmental Disorders - A Free Webinar from the Brain & Behavior Research Foundation
08 févr. 2023 13h23 HE
|
Brain & Behavior Research Foundation
New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Therapeutic Targeting of the Microbiome for Neurodevelopmental Disorders”...
ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits
01 févr. 2023 08h30 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
31 janv. 2023 09h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 31, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating...